SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.

被引：4
|
作者：
Ascierto, Paolo Antonio
Dummer, Reinhard
Melero, Ignacio
Palmieri, Giuseppe
Giannarelli, Diana
Abrami, Elena
Curvietto, Marcello
Simeone, Ester
Grimaldi, Antonio Maria
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS9598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9598
引用
收藏
页数：5
相关论文
共 3 条
  • [1] SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
    Ascierto, P. A.
    Mandala, M.
    Ferrucci, P. F.
    Rutkowski, P.
    Guidoboni, M.
    Fernandez, A. M. Arance
    Ferraresi, V.
    Maiello, E.
    Guida, M.
    Del Vecchio, M.
    Fierro, M. T.
    Queirolo, P.
    Lebbe, C.
    Helgadottir, H.
    Melero, I.
    Palmieri, G.
    Giannarelli, D.
    Grimaldi, A. M.
    Dummer, R.
    Sileni, V. Chiarion
    ANNALS OF ONCOLOGY, 2021, 32 : S1316 - S1317
  • [2] Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.
    Ascierto, Paolo Antonio
    Mandala, Mario
    Ferrucci, Pier Francesco
    Guidoboni, Massimo
    Rutkowski, Piotr
    Ferraresi, Virginia
    Arance, Ana Maria
    Guida, Michele
    Maiello, Evaristo
    Gogas, Helen
    Richtig, Erika
    Fierro, Maria Teresa
    Lebbe, Celeste
    Helgadottir, Hildur
    Bermejo, Ignacio Melero
    Palmieri, Giuseppe
    Giannarelli, Diana
    Grimaldi, Antonio Maria
    Dummer, Reinhard
    Chiarion-Sileni, Vanna
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation
    Ascierto, P. A.
    Mandala, M.
    Ferrucci, P. F.
    Guidoboni, M.
    Rutkowski, P.
    Ferraresi, V.
    Arance Fernandez, A. M.
    Guida, M.
    Maiello, E.
    Gogas, H. J.
    Richtig, E.
    Fierro, M. T.
    Lebbe, C.
    Helgadottir, H.
    Melero, I.
    Palmieri, G.
    Giannarelli, D.
    Grimaldi, A. M.
    Dummer, R.
    Sileni, V. Chiarion
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1408 - S1409
1